You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
Merck
Harvard Business School
Baxter

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLAPARIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Olaparib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00494234 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer Active, not recruiting KuDOS Pharmaceuticals Limited Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.
NCT00494234 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer Active, not recruiting AstraZeneca Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.
NCT00494442 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer Active, not recruiting KuDOS Pharmaceuticals Limited Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
NCT00494442 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer Active, not recruiting AstraZeneca Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
NCT00515866 Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer Completed AstraZeneca Phase 1 2007-08-01 The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
NCT00516373 A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) Active, not recruiting AstraZeneca Phase 1 2005-07-01 To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients.
NCT00516438 Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan Completed KuDOS Pharmaceuticals Limited Phase 1 2007-07-01 The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olaparib

Condition Name

Condition Name for Olaparib
Intervention Trials
Ovarian Cancer 26
Breast Cancer 20
Recurrent Primary Peritoneal Carcinoma 9
Recurrent Fallopian Tube Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olaparib
Intervention Trials
Ovarian Neoplasms 55
Breast Neoplasms 42
Carcinoma 31
Neoplasms 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olaparib

Trials by Country

Trials by Country for Olaparib
Location Trials
United States 598
Canada 71
United Kingdom 64
Spain 49
Italy 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olaparib
Location Trials
New York 35
California 34
Massachusetts 32
Pennsylvania 30
Texas 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olaparib

Clinical Trial Phase

Clinical Trial Phase for Olaparib
Clinical Trial Phase Trials
Phase 4 2
Phase 3 26
Phase 2/Phase 3 4
[disabled in preview] 225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olaparib
Clinical Trial Phase Trials
Not yet recruiting 120
Recruiting 93
Active, not recruiting 31
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olaparib

Sponsor Name

Sponsor Name for Olaparib
Sponsor Trials
AstraZeneca 136
National Cancer Institute (NCI) 42
Merck Sharp & Dohme Corp. 16
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olaparib
Sponsor Trials
Other 226
Industry 210
NIH 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Mallinckrodt
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.